Month: August 2021

Hexagon Digital Wave, a business of Hexagon Composites has signed a commercial service agreement with a North American Type-4 (renewable) natural gas (RNG/CNG) transportation module OEM. The agreement covers Modal Acoustic Emission (MAE) requalification of their RNG/CNG modules. MAE enables the requalification of Type-4 cylinders without removal from the module, resulting in reduced downtime and operator overhead. The commercial service agreement has a potential value of USD 2 million (approx. NOK 17 million). Driving Energy Transformation “This commercial service agreement is another step in creating a unified expectation of safety and testing standards in the gaseous transport industry,” says Ryan Pennock, Head of Marketing and Business Development at Hexagon Digital Wave. “Our goal is to create a benchmark in digital safety in the compressed...

Tallinna Sadam invites its current and future shareholders and other interested parties to the Investors’ Day, which will take place on August 25 at 17.00 Estonian time in the recently opened cruise terminal at the Tallinn Old City Harbour. Valdo Kalm and Marko Raid, members of the Management Board of Tallinna Sadam, will introduce the company, give an overview of the financial results, talk about the impact of the corona crisis, current developments and future plans, and answer participants’ questions. After the presentations and the free-form discussion, everyone will have the opportunity to get acquainted with the new cruise terminal building and promenade. The event will be held in Estonian. The recording of the event will be published on the website of Tallinna Sadam. Due to the current coronavirus restrictions, we only...

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Financial results for the first half of 2021Order entry increased to CHF 449.6 million (H1 2020: CHF 374.0 million)Increase of 20.9% in local currencies or 20.2% in Swiss francsSales of CHF 454.0 million (H1 2020: CHF 310.0 million)Growth of 47.5% in local currencies or 46.5% in Swiss francs Both business segments with similar growth ratesReported operating profit before depreciation and amortization (EBITDA) of CHF 115.0 million (H1 2020: CHF 60.2 million)Reported EBITDA margin of 25.3% (H1 2020: 19.4%)Reported net profit of CHF 82.6 million (H1 2020: CHF 36.0 million)Reported earnings per share increased by 127.8% to CHF 6.88 (H1 2020: CHF 3.02)Outlook for organic full-year sales and reported EBITDA margin raisedOperating...

Investor Webinar and Conference Call PERTH, Western Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) — Perseus Mining Limited (“Perseus” or the “Company”) (TSX & ASX: PRU) is hosting an investor webinar and conference call to discuss its 2020-21 Full Year Results, which are anticipated for release around 8:30am AEST on Thursday August 26, 2021. CALL DETAILS Australia: Thursday August 26, 2021 (Perth – 7:00am) (Sydney/Melbourne – 9:00am) Canada: Wednesday August 25, 2021 (Toronto – 7:00pm) (Vancouver – 4:00pm) UK: Thursday August 26, 2021 (London – 12:00am) Register for the investor webinar at the link below: https://us02web.zoom.us/webinar/register/WN_uo-Gw41XQzWrcXyNESmRGA After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one...

Breast cancer one of several important indication expansion opportunities for the Telix portfolio First patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging of lobular breast cancer ‘OPALESCENCE’, a Phase II study to assess feasibility of using TLX250-CDx to detect carbonic anhydrase IX (CA91) expression in triple-negative breast cancer, now open for enrolment at ICO Nantes (France).MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces the initiation of two new investigator-led studies to evaluate the potential utility of the Company’s late-stage imaging portfolio in women’s health, initially in two sub-types of breast cancer with a significant unmet medical need. Both TLX591-CDx and TLX250-CDx have...